The article describes how Quality by Design principles can be applied to the drug substance manufacturing process of an Fc fusion protein. First, the quality attributes of the product were evaluated for their potential impact on safety and efficacy using risk management tools. Similarly, process parameters that have a potential impact on critical quality attributes (CQAs) were also identified through a risk assessment.
View Article and Find Full Text PDFRev Med Chir Soc Med Nat Iasi
June 1975
Med Interna (Bucur)
February 1970
Rev Med Chir Soc Med Nat Iasi
July 1968
Electroencephalogr Clin Neurophysiol
June 1967
Rev Med Chir Soc Med Nat Iasi
January 1968
Rev Med Chir Soc Med Nat Iasi
August 1967
Rev Med Chir Soc Med Nat Iasi
November 1966